藥品異動通知及新藥介紹  

藥品新增 

<23P176> Paliperidone (Invega ®) 3mg/ E.R. Tab.

<28T021>Tamsulosin HCl (Harnalidge D ®) 0.2mg/O.D.Tab.

 

新藥介紹 

<23P176>Paliperidone (Invega ®) 3mg/ E.R. Tab.

藥理作用 

Paliperidone is the major active metabolite of risperidone.

Its proposed therapeutic activity is antagonism of both the

Central dopamine Type 2 (D(2)) and serotonin Type 2

(5HT(2A)) receptors.

It also has antagonistic effects on the alpha-1 adrenergic,

alpha-2 adrenergic, and H1 histaminergic receptors .

適應症/劑量 

PO,

Adult

Schizoaffective disorder: initial 6 mg/day; may increase by

3 mg/day increments at intervals of more than 4 days,

Max. 12 mg/day.

Schizophrenia: initial 6 mg/day; may increase by 3 mg/day

increments at intervals of more than 5 days, Max. 12 mg/day.

 

NotePaliperidone extended-release tablet must be swallowed whole with liquid; do not chew, divide, or crush.

使用禁忌 

hypersensitivity to paliperidone, risperidone, or to any product

component.

懷孕危險分級 

C

不良反應 

Bradycardia, tachycardia (16% geriatric ),tachyarrhythmia

(12-14% ), hypotension, ischemia, prolongation of QTc interval;

hyperprolactinemia (geriatric, 45-49% ), weight gain (4- 9% );

abdominal pain (1- 3%), increased appetite (2- 3%), dry mouth

(1-3%), constipation (4- 5% ), indigestion (5- 6% ); akathisia

(3-10% ), dizziness(7% geriatric), headache(11-14%),

extrapyramidal disease (2-20% ), somnolence (6- 12% );

nasopharyngitis (2- 5% ); agranulocytosis, leucopenia,

neutropenia; priapism; anaphylactic shock(rare). 

健保規定 

1.使用需合乎衛生主管機關許可之適應症範圍(paliperidone衛署許可適應症:精神分裂症),並需符合下列條件:

(1)開始使用「第二代抗精神病藥品」時需於病歷記載:醫療理由或診斷,以及臨床整體評估表 (Clinical Global Impression,簡稱CGI) 之分數。

 (2)經規則使用六至八週後,需整體評估其療效,並於病歷記載:臨床整體評估表之分數。

(3) paliperidone日劑量超過12mg/day時,須於病歷記載理由。

2.本類藥品不得使用於雙極性疾患之鬱症發作。

藥品圖檔

 

<28T021>Tamsulosin HCl (Harnalidge D ®) 0.2mg/O.D.Tab.

藥理作用

Tamsulosin hydrochloride, an alpha(1A) adrenoceptor antagonist, selectively blocks sympathetic nervous stimulation of the receptor resulting in relaxation of the smooth muscles of the prostate, prostatic urethra and bladder neck .

適應症/劑量

Oral dissolution,

Adult

Benign prostatic hyperplasia: initial, 0.4 mg QD; if no response

after 2 to 4 wk, may increase dose to 0.8 mg QD.

 

Note:Take after meals. Don’t c chew, divide, or crush. Place the

tablet on top of the tongue,it will dissolve; then swallow it with

saliva or require water to aid dissolution and swallowing.

使用禁忌

hypersensitivity to tamsulosin or to any component of the

product

懷孕危險分級

B

不良反應

Infectious disease (9-10.8% ); backache (7- 8.3% ), arthralgia

(11%), arthritis ( 5%), Myalgia (5%); asthenia (7.8- 8.5% ),

dizziness (14.9- 17.1% ), vertigo (0.6- 1%)headache (19.3-

21.1% ), insomnia (1.4- 2.4% ), somnolence (3- 4.3% );

priapism (rare ), decreased libido (1- 2%), abnormal ejaculation

(8.4- 18.1% ); rhinitis (13.1- 17.9% ), cough (3.4- 4.5%),

pharyngitis (5.1- 5.8%), sinusitis (2.2- 3.7%); blurred vision

(0.2- 2%), retinal detachment; chest pain(4- 4.1%), postural

hypotension( 0.2- 0.4%); allergic-type reactions; diarrhea (4.3-

6.2%), nausea (2.6- 3.9%).

健保規定

無相關規定

藥品圖檔

                           

 

藥劑科藥管組99.05.26

創作者介紹

【奇美藥丸子】- 醫藥‧健康‧樂活

Sam080477 發表在 痞客邦 PIXNET 留言(0) 人氣()